SIRT1 and familial pancreatic carcinoma: Consequently, targeting SIRT1 represents a promising therapeutic strategy for overcoming drug resistance and improving treatment outcomes in this aggressive malignancy, underscoring its potential as a strategic target for intervention in pancreatic cancer.